文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺癌磁共振引导自适应放疗:MOMENTUM研究——基于证据引入磁共振引导自适应放疗的国际注册研究首批结果

Magnetic Resonance-Guided Adaptive Radiation Therapy for Prostate Cancer: The First Results from the MOMENTUM study-An International Registry for the Evidence-Based Introduction of Magnetic Resonance-Guided Adaptive Radiation Therapy.
PubMed 文献 · Pract Radiat Oncol · 2022-11-30

MOMENTUM国际注册研究报道首批在1.5T磁共振直线加速器上接受5×7.25 Gy超低分割磁共振引导放疗的局限性前列腺癌患者12个月结局。共纳入425例患者,前列腺特异抗原中位值在12个月随访时显著下降,泌尿生殖系统和胃肠道CTCAE≥2级毒性峰值在3个月随访时分别为18.7%和1.7%。作者结论认为该治疗有效且安全,数据有助于患者教育和未来比较效果研究设计。

要点

  • 425例局限性前列腺癌患者接受5×7.25 Gy超低分割磁共振引导放疗。
  • 3个月随访时泌尿生殖系统和胃肠道CTCAE≥2级毒性分别为18.7%和1.7%。
  • 非ADT组医生报告和患者报告勃起功能从基线至12个月随访显著恶化。

核心结论

  • 作者结论认为,使用1.5T磁共振直线加速器对局限性前列腺癌进行超低分割磁共振引导放疗有效且安全。
  • CTCAE泌尿生殖系统和胃肠道毒性峰值报告于3个月随访时。
  • 对于未接受ADT的患者,12个月随访时报告CTCAE勃起功能障碍显著增加。
  • 这些数据有助于对患者进行预期结局教育,并为未来比较效果研究的设计提供信息。

研究设计与样本

  • 国际 consortium(MOMENTUM研究)注册研究,报告首批在1.5T磁共振直线加速器系统上接受超低分割放疗的局限性前列腺癌患者12个月结局。
  • 纳入接受5×7.25 Gy治疗的患者,共425例局限性前列腺癌(11.4%低危、82.0%中危、6.6%高危)。
  • 分别有365例、313例和186例患者达到3个月、6个月和12个月随访。
  • 在基线和随访3、6、12个月时记录前列腺特异抗原水平、医生报告的毒性(CTCAE)和患者报告结局(QLQ-PR25和QLQ-C30问卷)。
  • 采用配对比较统计方法比较基线与随访结局。

主要发现

  • 非ADT组和ADT组的前列腺特异抗原中位值在12个月随访时分别显著下降至1.2 ng/mL和0.1 ng/mL。
  • 泌尿生殖系统和胃肠道CTCAE毒性峰值报告于3个月随访时,≥2级分别为18.7%和1.7%。
  • QLQ-PR25问卷显示泌尿领域评分在所有随访时间点显著恶化:基线8.3(IQR 4.1-16.6),3个月12.4(IQR 8.3-24.8;P = .005),6个月12.4(IQR 8.3-20.8;P = .018),12个月12.4(IQR 8.3-20.8;P = .001)。
  • 非ADT组医生报告和患者报告的勃起功能从基线至12个月随访显著恶化。

临床怎么用

  • 作者认为这些数据有助于对患者进行预期结局教育,并为未来比较效果研究的设计提供信息。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Magnetic resonance (MR)-guided radiation therapy (MRgRT) is a new technique for treatment of localized prostate cancer (PCa). We report the 12-month outcomes for the first PCa patients treated within an international consortium (the MOMENTUM study) on a 1.5T MR-Linac system with ultrahypofractionated radiation therapy. METHODS AND MATERIALS: Patients treated with 5 × 7.25 Gy were identified. Prostate specific antigen-level, physician-reported toxicity (Common Terminology Criteria for Adverse Events [CTCAE]), and patient-reported outcomes (Quality of Life Questionnaire PR25 and Quality of Life Questionnaire C30 questionnaires) were recorded at baseline and at 3, 6, and 12 months of follow-up (FU). Pairwise comparative statistics were conducted to compare outcomes between baseline and FU. RESULTS: The study included 425 patients with localized PCa (11.4% low, 82.0% intermediate, and 6.6% high-risk), and 365, 313, and 186 patients reached 3-, 6-, and 12-months FU, respectively. Median prostate specific antigen level declined significantly to 1.2 ng/mL and 0.1 ng/mL at 12 months FU for the nonandrogen deprivation therapy (ADT) and ADT group, respectively. The peak of genitourinary and gastrointestinal CTCAE toxicity was reported at 3 months FU, with 18.7% and 1.7% grade ≥2, respectively. The QLQ-PR25 questionnaire outcomes showed significant deterioration in urinary domain score at all FU moments, from 8.3 (interquartile range [IQR], 4.1-16.6) at baseline to 12.4 (IQR, 8.3-24.8; P = .005) at 3 months, 12.4 (IQR, 8.3-20.8; P = .018;) at 6 months, and 12.4 (IQR, 8.3-20.8; P = .001) at 12 months. For the non-ADT group, physician- and patient-reported erectile function worsened significantly between baseline and 12 months FU. CONCLUSIONS: Ultrahypofractionated MR-guided radiation therapy for localized PCa using a 1.5T MR-Linac is effective and safe. The peak of CTCAE genitourinary and gastrointestinal toxicity was reported at 3 months FU. Furthermore, for patients without ADT, a significant increase in CTCAE erectile dysfunction was reported at 12 months FU. These data are useful for educating patients on expected outcomes and informing study design of future comparative-effectiveness studies.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Teunissen FR, Willigenburg T, Tree AC, et al. Magnetic Resonance-Guided Adaptive Radiation Therapy for Prostate Cancer: The First Results from the MOMENTUM study-An International Registry for the Evidence-Based Introduction of Magnetic Resonance-Guided Adaptive Radiation Therapy. Pract Radiat Oncol. 2022. PMID: 36462619. doi:10.1016/j.prro.2022.09.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。